Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea

Pfizer

Status: Completed

Conditions: Metastatic Breast Cancer

Treatments: Drug: Patients who received Palbociclib as first line therapy in MBC setting

Study type: Observational

Funder types: Industry

Identifiers

NCT05132101

A5481167

Palbociclib HIRA (Other Identifier)

Details and patient eligibility

About

The objective of this study is to evaluate the real-world prescription patterns of Palbociclib in breast cancer (BC) patients who were treated with Palbociclib in combination with AI as a 1st line of therapy using the national health insurance claims data in South Korea.

Enrollment: 2,758 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who were prescribed with palbociclib in combination with AI for at least 1 cycle during the index period
• Patients who were diagnosed with BC during the index period

Exclusion criteria

• Male
• Prescribed with palbociclib during 12-month period preceding the index date